Use of the CD2 signaling domain in second-generation chimeric antigen receptors
The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.
1. A cell comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), the CAR comprising an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the costimulatory signaling region comprises a CD2 signaling domain, wherein the nucleic acid comprises the nucleic acid sequence of SEQ ID NO: 1.
2. The cell of claim 1 , wherein the cell is selected from the group consisting of a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), and a regulatory T cell.
3. The cell of claim 1 , wherein the cell exhibits an anti-tumor immunity when the antigen binding domain binds to its corresponding antigen.